Leukemia drug spectrila tested in adults: phase 2 trial looks at drug levels and safety
NCT ID NCT03156790
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug Spectrila (a form of L-asparaginase) in 40 adults aged 18-55 with newly diagnosed B-cell acute lymphoblastic leukemia. The goal was to see if the drug reached effective levels in the blood and to check its safety and immune response. The trial was terminated early, but Spectrila is already approved in Europe for first-line treatment of all ages.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE B CELL LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Estadual Mario Covas
Santo André, 09190 615, Brazil
-
Hospital Rio Grande Natal
Natal, 59020-100, Brazil
-
Hospital das Clínicas São Paulo USP
Ribeirão Preto, 14048-900, Brazil
-
Hospital das Clínicas da UFG
Goiânia, 74605-020, Brazil
-
Hospital das Clínicas da Universidade Federal de Minas Gerais
Belo Horizonte, 30130-100, Brazil
-
Hospital de Clínicas Porto Alegre
Pôrto Alegre, 90035-903, Brazil
-
INCA Instituto Nacional do Cancer
Rio de Janeiro, 20231-048, Brazil
-
Universidade Estadual de Campinas
Campinas, 13083-878, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.